Related Experiment Videos
A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1
1Department of Internal Medicine, Medical College of Virginia, Richmond 23298, USA.
Anti-Cancer Drugs
|June 1, 1995
Summary
A new assay uses human platelets to measure blood levels of bryostatin 1, a cancer drug. This sensitive method can detect nanomolar concentrations, aiding clinical trials.
Area of Science:
- Pharmacology
- Biochemistry
- Oncology
Background:
- Bryostatin 1, a protein kinase C (PKC) activator, shows antitumor potential.
- Clinical trials are limited by the lack of sensitive assays for bryostatin 1 blood levels.
Purpose of the Study:
- Develop a sensitive assay for plasma bryostatin 1 levels.
- Utilize human platelet aggregation in response to bryostatin 1.
Main Methods:
- Exposing platelet-rich plasma to varying bryostatin 1 concentrations (5-100 nM).
- Measuring platelet aggregation lag phase and rate.
- Quantifying ATP release at higher concentrations (10-100 nM).
- Assessing bryostatin 1 in anticoagulated blood using platelet-poor plasma.
Main Results:
- A linear relationship was found between bryostatin 1 levels (2-25 nM) and aggregation parameters (R=0.976).
- ATP release correlated linearly with bryostatin 1 (10-100 nM, R=0.992).
- The assay detected concentrations as low as 5 nM by measuring aggregation lag phase delay.
Conclusions:
- A sensitive assay for nanomolar plasma bryostatin 1 levels was developed using platelet aggregation.
- This assay can quantify low bryostatin 1 concentrations, aiding pharmacokinetic and pharmacodynamic studies in clinical trials.